United States $124 Billion Medical Technology Giant Medtronic Diabetes Insulin Subsidiary MiniMed Group Nasdaq IPO to Raise $784 Million at $7.9 Billion Valuation with Expected IPO Listing on 5th March 2026, MiniMed Group Founded in 1983 by Alfred Mann & Acquired by Medtronic in 2001
27th February 2026 | Hong Kong
United States medical technology giant Medtronic ($124 billion market value) diabetes insulin subsidiary MiniMed Group Nasdaq IPO is raising $784 million at $7.9 billion valuation, with expected IPO listing on 5th March 2026. MiniMed Group was founded in 1983 by Alfred Mann, and acquired by Medtronic in 2001. MiniMed – MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we’ve pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes. Medtronic – Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.
“ United States $124 Billion Medical Technology Giant Medtronic Diabetes Insulin Subsidiary MiniMed Group Nasdaq IPO to Raise $784 Million at $7.9 Billion Valuation with Expected IPO Listing on 5th March 2026, MiniMed Group Founded in 1983 by Alfred Mann & Acquired by Medtronic in 2001 “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
United States $124 Billion Medical Technology Giant Medtronic Diabetes Insulin Subsidiary MiniMed Group Nasdaq IPO to Raise $784 Million at $7.9 Billion Valuation with Expected IPO Listing on 5th March 2026, MiniMed Group Founded in 1983 by Alfred Mann & Acquired by Medtronic in 2001
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
